retatrutide phase 3 trial dosing schedule Reta clinical data & — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in trials for metabolic health — targeting GLP-1, GIP Eli Lilly's Phase 3 clinical

2026 Jan;28(1):83-93

However, starting in July 2026, a new program called the BALANCE Model may give eligible Medicare Part D beneficiaries access to certain GLP-1 weight loss medications for a $50 copay

Here's a quick comparison: While dosing schedules appear similar, retatrutide's triple-receptor mechanism (GLP-1 + GIP + glucagon) produces different effects than dual-agonists like tirzepatide or single-agonists like semaglutide

Check Out Our 5 Star Reviews Additional Services You May Like Botox Emsculpt Smartlipo Lip Fillers Liposuction HydraFacial Microneedling Skin Assessment Microdermabrasion Skin Rejuvenation Laser Hair Removal Chemical Peels Nonsurgical Vaginal Tightening 360 Liposuction Laser Liposuction Cynosure Picosure laser Daxxify IV Hydration DRIPBaR IV Therapy The DRIPBaR Infrared Sauna Steam Sauna Cold Plunges Heated Plunges Normatec Compressions Emtone O-Shot Juvederm Kybella SkinTyte Ultherapy BioTE Hormone Replacement Therapy Laser Vein Removal Hair Treatment Laser Tattoo Removal Laser Skin Resurfacing Microneedling Broadband Light Therapy Medical Weight Loss Vivace ShenB Cartessa Microneedling IV Therapy for Recovery Nutrition Aescape Massage Zero Gravity Massage Chairs Whole Body Cryotherapy Red Light Therapy Bed HBOT Hyperbaric Chamber Aescape AI Robotic Massage Chin Liposuction

For storage best practices, see our peptide storage guide

Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, et al